FindTrial
Sign In

Therapeutic drug monitoring and safety of voriconazole in patients with liver dysfunction

Therapeutic drug monitoring and safety of voriconazole in patients with liver dysfunction

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019334
Enrollment
Unknown
Registered
2018-11-06
Start date
2018-12-01
Completion date
Unknown
Last updated
2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive fungal infections

Interventions

Case series:Nil

Sponsors

The First Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged = 18 years; 2. Receiving intravenous voriconazole (Vfend) for prevention or treatment of invasive fungal infections.

Exclusion criteria

Exclusion criteria: 1. Absence of voriconazole plasma concentration; 2. Incomplete important dosing information or clinical data.

Design outcomes

Primary

MeasureTime frame
Plasma drug concentration;Adverse reaction rate;Clinical Index;—

Countries

China

Contacts

Public ContactCai changjie

The First Affiliated Hospital of Sun Yat-sen University

13570097848@163.com+86 13570097848

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026